Clinical

Jennifer Barrett is the senior editor for 

Articles

A community oncology practice implemented a team-based approach to utilizing biosimilars. 

Pharmacist-Driven Biosimilar Adoption Model Leads to Cost Savings 

The new model will test a new way to lower increasing drug prices for patients paying for drugs under Medicare Part B. 

Trump Announces New Drug Pricing Model Is Set for January 2021

How will biosimilars continue to affect the prescription product market in 2021?

Biosimilars May Lead to Improved Competition and Lower Costs

The advent of generic and biosimilar medicines for novel treatments has helped bridge the gap in the delivery of cancer care between the United States and India, according to the study. 

Study Compares Cost, Accessibility of Novel Cancer Drugs in US and India

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.


Studies Reveal Positive Results for Infliximab Biosimilar

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

Merck has announced the US launch of trastuzumab-dttb (Ontruzant), a biosimilar to trastuzumab (Herceptin), in both 150-mg single-dose vials and 420-mg multiple-dose vials.

Merck Announces US Launch of Trastuzumab Biosimilar

Officials with the FDA have approved a 420-mg multi-dose of trastuzumab-bttb (Ontruzant, Samsung Bioepis), a biosimilar referencing trastuzumab (Herceptin).

FDA Approves 420-mg Multi-Dose Vial of Trastuzumab Biosimilar

Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.